Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933219 | 0.93 | MEN1 (0.57) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL6538869 | 0.89 | MEN1 (0.63) | MEN1KMT2AALDH1A1PTPN2PTPN1 | |
| SCHEMBL15056984 | 0.86 | KMT2A (0.56) | MEN1KMT2AALDH1A1RECQLPTPN2 | |
| SCHEMBL7359155 | 0.85 | MEN1 (0.55) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL4508484 | 0.82 | MEN1 (0.57) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL6940524 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1RECQLNPC1 | |
| SCHEMBL6214741 | 0.81 | KMT2A (0.51) | MEN1KMT2AALDH1A1RECQLPTPN2 | |
| SCHEMBL28854887 | 0.81 | MEN1 (0.51) | MEN1KMT2AALDH1A1RECQLPTPN2 | |
| SCHEMBL28154516 | 0.81 | MMP8 (0.52) | KMT2AALDH1A1RECQLMMP8NPC1 | |
| SCHEMBL5555267 | 0.79 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6538007-B1 | Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
| EP-0866705-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5852045-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0866705-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | BCAT1, BCAT2, AGXT | MEN1 1023/4885KMT2A 3762/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.